Welcome to our dedicated page for Tourmaline Bio news (Ticker: TRML), a resource for investors and traders seeking the latest updates and insights on Tourmaline Bio stock.
Tourmaline Bio, Inc. (TRML) is a late-stage clinical biotechnology company dedicated to developing groundbreaking medicines for patients with severe immune diseases. Headquartered in Boston, MA, and Louisville, KY, Tourmaline Bio is at the forefront of biotechnological advancements with a focus on transformative cell therapies. The company's mission is to significantly enhance patients' lives by offering treatments that can potentially eradicate the need for chronic immunosuppression in organ transplant recipients and induce lasting remissions in individuals with severe autoimmune and immune-mediated disorders.
The centerpiece of Tourmaline Bio's innovation is TOUR006, a fully human monoclonal antibody that targets interleukin-6 (IL-6), a crucial proinflammatory cytokine implicated in numerous autoimmune and inflammatory diseases. The IL-6 antibody class, including anti-IL-6 and anti-IL-6 receptor (IL-6R) antibodies, has a proven track record spanning over two decades, serving more than a million patients globally. TOUR006 harnesses this extensive clinical and commercial experience to offer potential new treatments for life-altering conditions.
Founded on pioneering technology developed by Dr. Suzanne Ildstad, Tourmaline Bio operates its own state-of-the-art cell processing facility in Louisville. The company is backed by top-tier life sciences investors such as Blackstone Life Sciences, Longitude Capital, and Qiming Venture Partners USA, underscoring its robust financial foundation.
Tourmaline Bio is committed to advancing its clinical programs and is currently navigating the complex pathways of regulatory approvals and clinical trials. Despite the inherent uncertainties and potential delays in the biotech sector, the company remains steadfast in its vision. Tourmaline Bio continually engages in forward-looking statements, understanding the risks and challenges ahead, including the need for substantial additional capital and achieving successful clinical outcomes.
For the latest updates and developments, investors and stakeholders can refer to Tourmaline Bio's periodic filings with the Securities and Exchange Commission (SEC), including the detailed 'Risk Factors' section in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.
Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotech company, has announced its participation in two upcoming investor conferences. CEO Sandeep Kulkarni is scheduled to present at:
- H.C. Wainwright 26th Annual Global Investor Conference in New York on September 9, 2024 at 12:00 pm ET
- Cantor Global Healthcare Conference in New York on September 17, 2024 at 3:40 pm ET
Both presentations will be available via live webcast on the company's website under the 'Events and Presentations' section. Replays will be archived on the site after each event. Tourmaline Bio focuses on developing transformative medicines for immune and inflammatory diseases.
Tourmaline Bio (NASDAQ: TRML) reported its Q2 2024 financial results and business highlights. Key points include:
- First patient dosed in Phase 2 TRANQUILITY trial for cardiovascular risk in May 2024
- On track to initiate Phase 3 trial for Thyroid Eye Disease (TED) in H2 2024
- Added to Russell 2000® and Russell 3000® Indexes in June 2024
- Cash position of $334.4 million as of June 30, 2024, providing runway into 2027
- Q2 2024 net loss of $17.5 million, or $0.68 per share
- R&D expenses increased to $15.7 million, G&A expenses rose to $6.2 million
The company continues to advance its clinical programs for pacibekitug in TED and cardiovascular diseases, with key data readouts expected in 2025.
Tourmaline Bio (NASDAQ: TRML) presented the design of its Phase 2 TRANQUILITY study at the American Society of Preventive Cardiology Congress 2024. The study evaluates TOUR006's ability to reduce high-sensitivity C-reactive protein (hs-CRP) in patients with chronic kidney disease (CKD) and elevated hs-CRP, who are at higher risk of atherosclerotic cardiovascular disease (ASCVD).
The trial involves 120 patients with CKD stage 3 or 4 and hs-CRP ≥2 and <15 mg/L, randomized to receive subcutaneous TOUR006 at various doses or placebo. The primary endpoint is the change in hs-CRP levels. Topline data is expected in the first half of 2025, potentially advancing TOUR006 toward Phase 3 readiness for ASCVD and other cardiovascular diseases.
Tourmaline Bio announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024. Robinson has been with Tourmaline since last summer and has served as the Interim CFO and Treasurer since October 2023. He played a key role in Tourmaline's growth, including a reverse merger in October 2023 and a $172.5 million public offering in January 2024. Robinson brings nearly 15 years of biotech finance and operations experience, having worked at Korro Bio, Jounce Therapeutics, and Merrimack Pharmaceuticals. He holds a B.S. in Management and an M.S. in Accounting from Boston College and is a CPA.
Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company, announced that its CEO, Sandeep Kulkarni, will present at the Jefferies Global Healthcare Conference in New York. The presentation is scheduled for Thursday, June 6, 2024, at 2:30 pm ET. A live webcast and replay will be available on the Tourmaline Bio website.
Tourmaline Bio has dosed the first patient in its Phase 2 TRANQUILITY trial for TOUR006, a monoclonal antibody targeting IL-6 to treat atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular conditions. This randomized, double-blind, placebo-controlled trial involves patients with high inflammatory risk and chronic kidney disease. The trial aims to assess the drug's safety, pharmacokinetics, and pharmacodynamics, with results anticipated in the first half of 2025. If successful, TOUR006 could advance to Phase 3 by 2025, offering quarterly subcutaneous dosing and potentially positioning itself as a best-in-class treatment for ASCVD and related conditions.
Tourmaline Bio, Inc. reported its Q1 2024 financial results and recent business highlights. Initiatives include a Phase 2 trial for ASCVD and TED, a successful public offering, and $350.3 million in cash reserves. The company aims to improve the lives of patients with immune and inflammatory diseases.
FAQ
What is the current stock price of Tourmaline Bio (TRML)?
What is the market cap of Tourmaline Bio (TRML)?
What is Tourmaline Bio, Inc.?
What is the primary product of Tourmaline Bio?
Where is Tourmaline Bio headquartered?
Who founded the technology behind Tourmaline Bio?
What are the potential benefits of TOUR006?
What are the risks associated with investing in Tourmaline Bio?
Which investors back Tourmaline Bio?
What should investors do to stay updated on Tourmaline Bio?
What is the significance of IL-6 in Tourmaline Bio's research?
How can I contact Tourmaline Bio for investor relations?
